ALIMERA SCIENCES, INC. (NASDAQ:ALIM) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On October 2, 2019, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its expectations for its consolidated net revenue for the third quarter ended September 30, 2019. Specifically, Alimera stated that it expects to report consolidated net revenue for the third quarter of 2019 exceeding $12.8 million, which compares to $10.9 million for the second quarter of 2019 and $11.1 million in the third quarter of 2018. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01. Regulation FD.
In addition, Richard S. Eiswirth, Jr., Alimera’s President and Chief Executive Officer, stated in the press release: “In the U.S. in the third quarter we saw sequential growth over the second quarter, which supports our belief that we have successfully addressed the domestic sales force issues we experienced in the first half of the year.” He also noted: “Our international sales segment continues to exhibit strong growth, as we further penetrate into existing territories with ILUVIEN®’s two approved indications, diabetic macular edema and non-infectious posterior uveitis.” The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Forward Looking Statements
This Current Report on Form 8-K contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s expectations regarding its revenue for the third quarter of 2019 and its belief that it has addressed the domestic sales force issues. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change either of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors that could cause actual results to differ include, but are not limited to, (a) final accounting adjustments in Alimera’s revenue for the third quarter of 2019 may cause the actual reported amount to be different than stated above; (b) unexpected departures of members of Alimera’s sales force, or underperformance of that sales force, could occur; (c) Alimera’s revenue could decline due to a reduction in end user demand, unanticipated competition, regulatory issues, or other unexpected circumstances; and (d) other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2018 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, which are on file with the Securities and Exchange Commission and available on its website at http://www.sec.gov.
Item 9.01. Financial Statements and Exhibits.
ALIMERA SCIENCES INC Exhibit
EX-99.1 2 exhibit991pr.htm EXHIBIT 99.1 Exhibit Exhibit 99.1FOR IMMEDIATE RELEASE For press inquiries:Jules Abrahamfor Alimera Sciences [email protected]
investor inquiries:Scott Gordonfor Alimera [email protected]
Sciences Announces Top Line Revenue ExpectationFor the Third Quarter of 2019 Consolidated net revenue expected to exceed $12.8 million ATLANTA,…
To view the full exhibit click
About ALIMERA SCIENCES, INC. (NASDAQ:ALIM)
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
An ad to help with our costs